



Product Information

Product ID C0006

CAS No. 849217-68-1

Chemical Name N-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide

Synonym XL-184, BMS-907351

Formula C₂₈H₂₄FN₃O₅

Formula Wt. 501.51

Melting Point


Purity ≥98%

Solubility Soluble in DMSO
(≥117mg/mL), insoluble in
water (≤1 mg/mL).

Store Temp Ambient

Ship Temp Ambient

Description Cabozantinib is an anticancer chemotherapeutic compound that has been approved to treat medullary thyroid cancer and is in clinical trials as a treatment for other types of solid tumors. Cabozantinib exerts its anticancer activity through inhibition of Met, RET, and VEGFR2, increasing apoptosis and inhibiting cell growth and osteoclast proliferation in vitro and in vivo.



Bulk quantities available upon request

Product ID	Size
C0006	10 mg
C0006	25 mg
C0006	100 mg
C0006	250 mg

References Dai J, Zhang H, Karatsinides A, et al. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. Clin Cancer Res. 2013 Oct 4. [Epub ahead of print]. PMID: 24097861.

Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10;31(29):3639-46. PMID: 24002501.

Bentzien F, Zuzow M, Heald N, et al. In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer. Thyroid. 2013 Sep 17. [Epub ahead of print]. PMID: 23705946.

Navis AC, Bourgonje A, Wesseling P, et al. Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2. PLoS One. 2013;8(3):e58262. PMID: 23484006.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.